PE20081366A1 - Formulacion acuosa que comprende acido (2r)-2-[4-(7-bromo-2-quinoliloxi)fenoxi]propanoico - Google Patents
Formulacion acuosa que comprende acido (2r)-2-[4-(7-bromo-2-quinoliloxi)fenoxi]propanoicoInfo
- Publication number
- PE20081366A1 PE20081366A1 PE2007001187A PE2007001187A PE20081366A1 PE 20081366 A1 PE20081366 A1 PE 20081366A1 PE 2007001187 A PE2007001187 A PE 2007001187A PE 2007001187 A PE2007001187 A PE 2007001187A PE 20081366 A1 PE20081366 A1 PE 20081366A1
- Authority
- PE
- Peru
- Prior art keywords
- quinolyloxy
- phenoxy
- bromo
- cyclodextrin
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A UNA FORMULACION ACUOSA QUE COMPRENDE: i) UN AGENTE ANTICANCERIGENO: ACIDO (2R)-2-[4-(7-BROMO-2-QUINOLILOXI)FENOXI]PROPANOICO PRESENTE EN UNA CANTIDAD ENTRE 0,1% A 5% (P/V); ii) UNA CICLODEXTRINA SELECCIONADA DEL GRUPO DE ALFA, BELTA, GAMMA Y DELTA-CICLODEXTRINAS, SIENDO PREFERIDAS SULFOBUTIL ETER ß-CICLODEXTRINA E HIDROXI-PROPIL ß-CICLODEXTRINA, CAPTISOL, PRESENTE EN UNA CANTIDAD ENTRE 1% A 50% (P/V); Y iii) AL MENOS UN AGENTE POTENCIADOR DE SOLUBILIDAD, TAL COMO UN AGENTE TAMPONANTE SIENDO PREFERIDO TAMPON FOSFATO DE METAL MONOALCALINO/FOSFATO DE METAL DIALCALINO EN UNA CONCENTRACION ENTRE 0,01 M A 0,25 M Y UN pH ENTRE 5 Y 8. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTA FORMULACION SE CARACTERIZA POR SER MEJORADA YA QUE REDUCE LA HEMOLISIS CAUSADA POR EL FARMACO, SIENDO DE ADMINISTRACION PARENTERAL, Y UTIL EN EL TRATAMIENTO DE UN CANCER SOLIDO TAL COMO CANCER DE COLON, MAMA, PROSTATA, OVARIO, MELANOMA Y PANCREAS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06291410A EP1897542A1 (en) | 2006-09-07 | 2006-09-07 | Aqueous formulation comprising an antitumor agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20081366A1 true PE20081366A1 (es) | 2008-11-28 |
Family
ID=37728353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007001187A PE20081366A1 (es) | 2006-09-07 | 2007-09-05 | Formulacion acuosa que comprende acido (2r)-2-[4-(7-bromo-2-quinoliloxi)fenoxi]propanoico |
Country Status (16)
| Country | Link |
|---|---|
| EP (2) | EP1897542A1 (es) |
| JP (1) | JP2010502691A (es) |
| KR (1) | KR20090050070A (es) |
| CN (1) | CN101511362A (es) |
| AR (1) | AR062674A1 (es) |
| AU (1) | AU2007293174A1 (es) |
| BR (1) | BRPI0717034A2 (es) |
| CA (1) | CA2660685A1 (es) |
| CL (1) | CL2007002598A1 (es) |
| IL (1) | IL197072A0 (es) |
| MX (1) | MX2009002280A (es) |
| PE (1) | PE20081366A1 (es) |
| RU (1) | RU2009112624A (es) |
| TW (1) | TW200817005A (es) |
| UY (1) | UY30579A1 (es) |
| WO (1) | WO2008029282A2 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10463677B2 (en) | 2008-11-07 | 2019-11-05 | Cydex Pharmaceuticals, Inc. | Composition containing sulfoalkyl ether cyclodextrin and latanoprost |
| WO2012175434A1 (en) | 2011-06-20 | 2012-12-27 | Glaxo Group Limited | Pharmaceutical formulations comprising vestipitant |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2456173A1 (en) * | 2001-07-31 | 2003-02-13 | Wayne State University | Quinoline derivatives and use thereof as antitumor agents |
| UA79293C2 (en) * | 2002-07-03 | 2007-06-11 | Univ Wayne State | 4-(7'-halo-2-quino (xa-) linyloxy)phenoxy propionic acid derivatives as antineoplastic agents |
-
2006
- 2006-09-07 EP EP06291410A patent/EP1897542A1/en not_active Withdrawn
-
2007
- 2007-08-22 TW TW096131093A patent/TW200817005A/zh unknown
- 2007-09-05 PE PE2007001187A patent/PE20081366A1/es not_active Application Discontinuation
- 2007-09-06 WO PCT/IB2007/003480 patent/WO2008029282A2/en active Application Filing
- 2007-09-06 MX MX2009002280A patent/MX2009002280A/es not_active Application Discontinuation
- 2007-09-06 CA CA002660685A patent/CA2660685A1/en not_active Abandoned
- 2007-09-06 KR KR1020097004783A patent/KR20090050070A/ko not_active Application Discontinuation
- 2007-09-06 CL CL200702598A patent/CL2007002598A1/es unknown
- 2007-09-06 EP EP07825658A patent/EP2068876A2/en not_active Withdrawn
- 2007-09-06 CN CNA2007800330654A patent/CN101511362A/zh active Pending
- 2007-09-06 AU AU2007293174A patent/AU2007293174A1/en not_active Abandoned
- 2007-09-06 JP JP2009527226A patent/JP2010502691A/ja not_active Withdrawn
- 2007-09-06 RU RU2009112624/15A patent/RU2009112624A/ru unknown
- 2007-09-06 AR ARP070103931A patent/AR062674A1/es unknown
- 2007-09-06 BR BRPI0717034-3A2A patent/BRPI0717034A2/pt not_active IP Right Cessation
- 2007-09-07 UY UY30579A patent/UY30579A1/es not_active Application Discontinuation
-
2009
- 2009-02-16 IL IL197072A patent/IL197072A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2007002598A1 (es) | 2008-04-18 |
| JP2010502691A (ja) | 2010-01-28 |
| RU2009112624A (ru) | 2010-10-20 |
| AR062674A1 (es) | 2008-11-26 |
| MX2009002280A (es) | 2009-03-13 |
| CA2660685A1 (en) | 2008-03-13 |
| AU2007293174A1 (en) | 2008-03-13 |
| UY30579A1 (es) | 2008-03-31 |
| EP1897542A1 (en) | 2008-03-12 |
| EP2068876A2 (en) | 2009-06-17 |
| WO2008029282A2 (en) | 2008-03-13 |
| IL197072A0 (en) | 2009-11-18 |
| CN101511362A (zh) | 2009-08-19 |
| TW200817005A (en) | 2008-04-16 |
| BRPI0717034A2 (pt) | 2014-05-20 |
| WO2008029282A3 (en) | 2008-05-22 |
| KR20090050070A (ko) | 2009-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20091328A1 (es) | Formulacion de anticuerpo | |
| AR122463A2 (es) | Suspensiones de nanopartículas que contienen polímero de carboxivinilo | |
| EA201200475A1 (ru) | Высококонцентрированные фармацевтические композиции, содержащие антитело к cd20 | |
| BRPI0905080B8 (pt) | composição de sulfoalquil éter ciclodextrina (sae-cd), processos para preparar uma composição de sulfoalquil éter ciclodextrina (sae-cd), processo para preparar uma composição e produto | |
| Rao et al. | Chitosan-decorated selenium nanoparticles as protein carriers to improve the in vivo half-life of the peptide therapeutic BAY 55-9837 for type 2 diabetes mellitus | |
| MX365138B (es) | Inhibidores de prolil hidroxilasa. | |
| MX2016017117A (es) | Conjugados de anticuerpo her2-farmaco. | |
| EA200870219A1 (ru) | Стабилизированные сукцинатом витамина е фармацевтические композиции, способы их получения и применения | |
| NZ599045A (en) | New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody | |
| GEP20125628B (en) | Pharmaceutical compositions containing antagonist anti-cd40 antibody | |
| EP3778917A3 (en) | Multispecific antibodies, antibody analogs, compositions, and methods | |
| Trouet et al. | Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: application to doxorubicin and preliminary in vitro and in vivo studies | |
| BRPI0814957B8 (pt) | composto, agente farmacêutico, e, uso do composto | |
| MY188326A (en) | Agricultural chemical-spreading agent composition | |
| CO7270463A2 (es) | Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición | |
| DE602004030017D1 (de) | Heterocyclische verbindungen als nützliche malonyl-coa decarboxylase-hemmer | |
| EA201100762A1 (ru) | Состав, содержащий октенидин | |
| PE20081366A1 (es) | Formulacion acuosa que comprende acido (2r)-2-[4-(7-bromo-2-quinoliloxi)fenoxi]propanoico | |
| NZ598518A (en) | Concentrated polypeptide formulations with reduced viscosity | |
| CL2009002167A1 (es) | Formulacion farmaceutica para administracion endovenosa que comprende un compuesto derivado de conjugados de camptotecina-polimero biocompatibles y biodegradables, un agente de estabilizacion, uno o varios tampones y un tensoactivo, util para el tratamiento del cancer. | |
| GB2462761A (en) | Protein formulation | |
| TN2012000516A1 (en) | Stable ready to use injectable paracetamol formulation | |
| BR112014016723A2 (pt) | método para o tratamento de câncer de mama | |
| MX2023013995A (es) | Conjugados de anticuerpo y antraciclina. | |
| MX347677B (es) | Formulacion farmaceutica entre jasmonatos y sus derivados y nanoportadores o microportadores. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |